293 related articles for article (PubMed ID: 21121684)
1. Synthetic and mechanistic pathways of cis and trans-hydroxytamoxifen drug derivatives reacting with Cp*Rh complexes that involve η1-N, η2-N,O, η1-O, and η6 bonding modes, via a novel N-π rearrangement; relative binding affinities and computer docking studies of cis and trans-η6-Cp*Rh-hydroxytamoxifen complexes at the estrogen, ERα and ERβ receptors, and growth inhibition to breast cancer cells.
Top S; Efremenko I; Rager MN; Vessières A; Yaswen P; Jaouen G; Fish RH
Inorg Chem; 2011 Jan; 50(1):271-84. PubMed ID: 21121684
[TBL] [Abstract][Full Text] [Related]
2. A DFT study on the mechanism of a novel, regioselective, intramolecular N-pi rearrangement of cis and trans-eta1-N-Cp*Rh-hydroxytamoxifen complexes to their eta6 derivatives; potential breast cancer pharmaceuticals, and fluorescent probes.
Efremenko I; Top S; Martin JM; Fish RH
Dalton Trans; 2009 Jun; (22):4334-43. PubMed ID: 19662311
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
[TBL] [Abstract][Full Text] [Related]
4. Selective estrogen receptor modulators in the ruthenocene series. Synthesis and biological behavior.
Pigeon P; Top S; Vessières A; Huché M; Hillard EA; Salomon E; Jaouen G
J Med Chem; 2005 Apr; 48(8):2814-21. PubMed ID: 15828819
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationships of ferrocenyl tamoxifen derivatives with modified side chains.
Nguyen A; Top S; Pigeon P; Vessières A; Hillard EA; Plamont MA; Huché M; Rigamonti C; Jaouen G
Chemistry; 2009; 15(3):684-96. PubMed ID: 19053086
[TBL] [Abstract][Full Text] [Related]
6. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
7. Role of aromatic substituents on the antiproliferative effects of diphenyl ferrocenyl butene compounds.
Zekri O; Hillard EA; Top S; Vessières A; Pigeon P; Plamont MA; Huché M; Boutamine S; McGlinchey MJ; Müller-Bunz H; Jaouen G
Dalton Trans; 2009 Jun; (22):4318-26. PubMed ID: 19662309
[TBL] [Abstract][Full Text] [Related]
8. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
[TBL] [Abstract][Full Text] [Related]
9. Diastereomerically pure platinum(II) complexes as antitumoral agents.: The influence of the mode of binding {(N), (N,O)- or (C,N)}- of (1S,2R)[(η5-C5H5)Fe{(η5-C5H4)CHNCH(Me)CH(OH)C6H5}] and the arrangement of the auxiliary ligands.
Talancón D; López C; Font-Bardía M; Calvet T; Quirante J; Calvis C; Messeguer R; Cortés R; Cascante M; Baldomà L; Badia J
J Inorg Biochem; 2013 Jan; 118():1-12. PubMed ID: 23123334
[TBL] [Abstract][Full Text] [Related]
10. C-C coupling reactions in the coordination sphere of rhodium(I) and rhodium(III): New routes for the di- and trimerization of terminal alkynes.
Schafer M; Wolf J; Werner H
Dalton Trans; 2005 Apr; (8):1468-81. PubMed ID: 15824785
[TBL] [Abstract][Full Text] [Related]
11. Syntheses and electronic properties of rhodium(III) complexes bearing a redox-active ligand.
Wanniarachchi S; Liddle BJ; Kizer B; Hewage JS; Lindeman SV; Gardinier JR
Inorg Chem; 2012 Oct; 51(20):10572-80. PubMed ID: 23035689
[TBL] [Abstract][Full Text] [Related]
12. Intramolecular alkyl phosphine dehydrogenation in cationic rhodium complexes of tris(cyclopentylphosphine).
Douglas TM; Brayshaw SK; Dallanegra R; Kociok-Köhn G; Macgregor SA; Moxham GL; Weller AS; Wondimagegn T; Vadivelu P
Chemistry; 2008; 14(3):1004-22. PubMed ID: 17992682
[TBL] [Abstract][Full Text] [Related]
13. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells.
Murphy LC; Peng B; Lewis A; Davie JR; Leygue E; Kemp A; Ung K; Vendetti M; Shiu R
J Mol Endocrinol; 2005 Apr; 34(2):553-66. PubMed ID: 15821116
[TBL] [Abstract][Full Text] [Related]
14. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
[TBL] [Abstract][Full Text] [Related]
15. The chemoselective reactions of tyrosine-containing G-protein-coupled receptor peptides with [Cp*Rh(H2O)3](OTf)2, including 2D NMR structures and the biological consequences.
Albada HB; Wieberneit F; Dijkgraaf I; Harvey JH; Whistler JL; Stoll R; Metzler-Nolte N; Fish RH
J Am Chem Soc; 2012 Jun; 134(25):10321-4. PubMed ID: 22671299
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen induces the expression of maspin through estrogen receptor-alpha.
Liu Z; Shi HY; Nawaz Z; Zhang M
Cancer Lett; 2004 Jun; 209(1):55-65. PubMed ID: 15145521
[TBL] [Abstract][Full Text] [Related]
18. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
19. Selective estrogen-receptor modulators (SERMs) in the cyclopentadienylrhenium tricarbonyl series: synthesis and biological behaviour.
Top S; Vessières A; Pigeon P; Rager MN; Huché M; Salomon E; Cabestaing C; Vaissermann J; Jaouen G
Chembiochem; 2004 Aug; 5(8):1104-13. PubMed ID: 15300835
[TBL] [Abstract][Full Text] [Related]
20. Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells.
Lee SO; Nadiminty N; Wu XX; Lou W; Dong Y; Ip C; Onate SA; Gao AC
Cancer Res; 2005 Apr; 65(8):3487-92. PubMed ID: 15833885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
